Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration

References

• Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends in anti-vascular endothelial growth factor use in ophthalmology among privately insured and medicare advantage patients. Ophthalmology. 2017;124:352–358. doi:10.1016/j.ophtha.2016.10.036
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 355;2006:1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, et al; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 116;2009:57–65. doi:10.1016/j.ophtha.2008.10.018
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–1908.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–1398. doi:10.1016/j.ophtha.2012.03.053
   PubMed Web of Science ®Google Scholar
• Kitchens JW, Do DV, Boyer DS, et al. Comprehensive review of ocular and systemic safety events with intravitreal aflibercept injection in randomized controlled trials. Ophthalmology. 2016;123:1511–1520. doi:10.1016/j.ophtha.2016.02.046
   PubMed Web of Science ®Google Scholar
• Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95:1111–1114. doi:10.1136/bjo.2010.180729
   PubMed Web of Science ®Google Scholar
• Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246:955–958. doi:10.1007/s00417-008-0819-2
   PubMed Web of Science ®Google Scholar
• Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. 2009;40:293–295. doi:10.3928/15428877-20090430-12
   PubMed Web of Science ®Google Scholar
• Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010;26:105–110. doi:10.1089/jop.2009.0076
   PubMed Web of Science ®Google Scholar
• Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma. 2012;21:241–247. doi:10.1097/IJG.0b013e31820d7d19
   PubMed Web of Science ®Google Scholar
• Loukianou E, Brouzas D, Apostolopoulos M. Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 mL ranibizumab. Int Ophthalmol. 2011;31:211–213. doi:10.1007/s10792-010-9410-z
   Google Scholar
• Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina. 2011;31:1028–1035. doi:10.1097/IAE.0b013e318217ffde
   PubMed Web of Science ®Google Scholar
• Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146:930–934. doi:10.1016/j.ajo.2008.07.007
   PubMed Web of Science ®Google Scholar
• Wen JC, Reina-Torres E, Sherwood JM, et al. Intravitreal anti-VEGF injections reduce aqueous outflow facility in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58:1893–1898. doi:10.1167/iovs.16-20786
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Moshfeghi DM, Francom S, et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Ophthalmology. 2014;121:1102–1108. doi:10.1016/j.ophtha.2013.11.029
   PubMed Web of Science ®Google Scholar
• Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology. 2015;122:1802–1810. doi:10.1016/j.ophtha.2015.04.018
   PubMed Web of Science ®Google Scholar
• Eadie BD, Etminan M, Carleton BC. Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery. JAMA Ophthalmol. 2017;135(4):363–368. doi:10.1001/jamaophthalmol.2017.0059
   PubMed Web of Science ®Google Scholar
• Atchison EA, Wood KM, Mattox CG, Barry CN, Lum F, MacCumber MW. The real-world effect of intravitreous anti-vascular endothelial growth factor drugs on intraocular pressure: an analysis using the IRIS Registry. Ophthalmology. 2018. doi:10.1016/j.ophtha.2017.11.027
   Web of Science ®Google Scholar
• Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21:2409–2419. doi:10.1002/(ISSN)1097-0258
   PubMed Web of Science ®Google Scholar
• Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80(1):27–38. doi:10.1093/biomet/80.1.27
   Web of Science ®Google Scholar
• Jiang X, Varma R, Wu S, et al. Baseline risk factors that predict the development of open-angle glaucoma in a population: the Los Angeles latino eye study. Ophthalmology. 2012;119:2245–2253. doi:10.1016/j.ophtha.2012.05.030
   PubMed Web of Science ®Google Scholar
• De Voogd S, Ikram MK, Wolfs RC, Jansonius NM, Hofman A, de Jong PT. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam study. Ophthalmology. 2005;112:1487–1493. doi:10.1016/j.ophtha.2005.04.018
   PubMed Web of Science ®Google Scholar
• Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mones J; on behalf of the TREND Study Group. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125:57–65. doi:10.1016/j.ophtha.2017.07.014
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug injections. Retina. 2008;28(7):996–1001. doi:10.1097/IAE.0b013e31816c6868
   PubMed Web of Science ®Google Scholar
• Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina. 2010;30(6):887–892. doi:10.1097/IAE.0b013e3181d50cea
   Web of Science ®Google Scholar
• Ricca AM, Morshedi RG, Wirostko BM. High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism. J Ocular Pharma Ther. 2015;31(1):2–10. doi:10.1089/jop.2014.0062
   Web of Science ®Google Scholar
• Reina-Torres E, Wen JC, Liu KC, et al. VEGF as a paracrine regulator of conventional outflow facility. Invest Ophthalmol Vis Sci. 2017;58:1899–1908. doi:10.1167/iovs.16-20779
   PubMed Web of Science ®Google Scholar
• Aref AA. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin Ophthalmol. 2012;23:105–110. doi:10.1097/ICU.0b013e32834ff41d
   PubMed Web of Science ®Google Scholar
• Kerimoglu H, Ozturk BT, Bozkurt B, Okka M, Okudan S. Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol. 2011;89(2):138–142. doi:10.1111/j.1755-3768.2009.01656.x
   PubMed Web of Science ®Google Scholar
• Alaghband P, Beltran-Agullo L, Galvis EA, Overby DR, Lim KS. Effect of phacoemulsification on facility of outflow. Br J Ophthalmol. 2018;102(11):1520–1526. doi:10.1136/bjophthalmol-2017-311548
   Web of Science ®Google Scholar
• Wen JC, Cousins SW, Schuman SG, Allingham RR. Dynamic changes of the anterior chamber angle produced by intravitreal anti-vascular growth factor injections. Retina. 2016;36(10):1874–1881. doi:10.1097/IAE.0000000000001018
   PubMed Web of Science ®Google Scholar